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Abstract The cause of lichen planus is still unknown.
Previously we showed human herpes virus 7 (HHV-7)
DNA and proteins in lesional lichen planus skin, and sig-
niﬁcantly less in non-lesional lichen planus, psoriasis or
healthy skin. Remarkably, lesional lichen planus skin was
inﬁltrated with plasmacytoid dendritic cells. If HHV-7 is
associated with lichen planus, then HHV-7 replication
would reduce upon lichen planus remission. HHV-7 DNA
detection was performed by nested PCR and HHV-7 pro-
tein by immunohistochemistry on lesional skin biopsies
from lichen planus patients before treatment and after
remission. Biopsies were obtained from lichen planus le-
sions before treatment (n = 18 patients) and after remission
(n = 13). Before treatment 61% biopsies contained HHV-7
DNA versus 8% after remission (P = 0.01). HHV-7-pro-
tein positive cell numbers diminished signiﬁcantly after
remission in both dermis and epidermis. Expression of
HHV-7 was mainly detected in BDCA-2 positive plasma-
cytoid dendritic cells rather than CD-3 positive lympho-
cytes. HHV-7 replicates in plasmacytoid dendritic cells in
lesional lichen planus skin and diminishes after remission.
This study further supports our hypothesis that HHV-7 is
associated with lichen planus pathogenesis.
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Introduction
Lichen planus is clinically characterized by ﬂat topped
polygonal, itchy erythematous papules with Wickams’
striae, nail deformation, and white mucosal patches [4].
The histopathological substrate comprises a dermal band
like (lichenoid) lymphocytic inﬁltrate directed towards the
basal epidermal layer with destruction of the basal mem-
brane and apoptosis of epidermal cells (colloid bodies). A
viral cause infecting skin cells has been proposed. Hepatitis
C virus was epidemiologically linked to lichen planus [14],
but this ﬁnding could not be conﬁrmed in later studies [13].
We recently described an association of human herpes
virus type 7 (HHV-7) DNA and large inﬁltrates of plas-
macytoid dendritic cells (associated with virally induced
inﬂammatory processes) in lesional skin of lichen planus
patients but not in non-lesional skin of the same patients
[5]. Moreover, skin of healthy volunteers and of patients
with another inﬂammatory skin condition like psoriasis
showed signiﬁcantly less HHV-7 activity. Others have
described plasmacytoid dendritic cell recruitment with
interferon-alpha and antiviral protein MxA production, in
oral and cutaneuous lichen planus lesions [16, 18]. The
presence of HHV-7 in lesional skin could play a role in the
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organism affecting more than 90% of the adult population
worldwide, and primary infection occurs mainly during
early childhood [1]. Like Epstein Barr virus reactivation is
associated with Burkitt lymphoma, reactivation of HHV-7
during adulthood could be associated with lichen planus.
To support this hypothesis, we quantiﬁed and compared the
presence of HHV-7 DNA and protein in lesional lichen
planus skin before, and after treatment-induced remission.
Materials and methods
The hospital medical ethics review board approved this
study. Before entering the study, patients gave their written
informedconsenttoparticipate.Skinbiopsieswerecollected
in a follow up study from the same patient group with lichen
planusasdescribedbefore[5].Inshort,beforetreatmentwas
initiated, two 4 mm full thickness skin biopsies were ob-
tained from lesional skin. Patients were treated with 40 mg
prednisone per os daily, diminished with 5 mg every other
dayuntiladailydoseof20 mgwas reached. From that point
on, the prednisone dosage was diminished with 5 mg per
week. If new lichen planus lesions recurred, the previous
dosewasadministeredanddiminishmenthaltedfor3 weeks.
In case prednisone treatment was contra-indicated, other
treatment options like topical corticosteroids, oral acitretin
(0.5 mg/kg body weight) and psoralen ultraviolet A com-
bined photo therapy were considered, depending on the ex-
tent of lesions and underlying medical conditions.
Treatment was terminated after complete clinical
remission was achieved and 2 weeks later, provided no
disease activity had recurred, another two biopsies were
collected from recovered lesional skin adjacent to the
pretreatment biopsy sites. Both time points biopsies were
taken, one biopsy was processed for routine histopathology
and examined by both a pathologist and a dermatologist
separately to conﬁrm the lichen planus diagnosis or signs
of ongoing inﬂammation. The ﬁnal diagnosis was made on
mutual agreement and based on typical lichen planus
associated dermatopathological signs like parakeratosis,
wedge shaped hypergranulosis, saw-tooth conﬁgured rete
ridges, vacuolar degeneration of the basal layer, colloid
bodies, a band-like dermal inﬂammatory inﬁltration and
pigment incontinence [17].
The second biopsy of each time point was snap frozen
in liquid nitrogen, stored at minus 80 C, and thawed later
for molecular biological analysis (HHV-7 DNA). DNA
isolation and the nested PCR techniques have been pre-
viously described [5, 12]. The ampliﬁed fragment
(296 bp) was identiﬁed by gel electrophoresis. The lower
limit of detection of the PCR is 1–5 copies of HHV-7
DNA.
We performed immunohistochemistry as described be-
fore [5, 11]. The antibodies used in this study were directed
against: HHV-7, clone 5E1 and clone KR4, both resulting
in a similar speciﬁc staining pattern (data not shown; Ad-
vanced Biotechnologies Inc., Columbia, MD), CD3 (pan T
cell marker; clone SK7, FITC-conjugated; BD Biosciences,
San Jose, CA), and BDCA-2 (plasmacytoid dendritic cell
marker; clone AC144, FITC conjugated; Miltenyi Biotec,
Bergisch Gladbach, Germany). In the single-staining
experiments we used clone 5E1 (directed against HHV-7
tegument protein pp85), but unfortunately this clone was
no longer available at the time we performed the double
staining. For this reason we used in the double staining
experiments clone KR4 (directed against an unknown
HHV-7 epitope). In brief the following sequence of steps
was applied for single staining: blocking endogenous per-
oxidase activity; anti-HHV-7 (clone 5E1); biotin-conju-
gated goat anti-mouse antibody (Dako); horseradish
peroxidase-conjugated streptavidin; and for clone KR4 a
TSA ampliﬁcation step (Perkin Elmer) was applied. In four
patients specimens obtained before and after remission
were double stained for HHV-7 and CD3 or for HHV-7 and
BDCA-2. In this case the following incubation steps were
performed: blocking endogenous peroxidase activity; anti-
HHV-7 (clone KR4); biotin-conjugated goat anti-mouse
antibody (Dako); horseradish peroxidase-conjugated
streptavidin; TSA ampliﬁcation according to the manu-
facturer’s protocol (Perkin Elmer); an AEC kit to visualize
the peroxidase activity (Vector); blocking potential avail-
able biotin, anti-mouse immunoglobulin, and peroxidase
activity; FITC-BDCA-2 or FITC-CD3 antibody; rabbit
anti-FITC (Dako); peroxidase-conjugated goat anti-rabbit
(Dako) for BDCA-2 and phosphatase-conjugated goat anti-
rabbit (Dako) for CD3; for BDCA-2 a TSA ampliﬁcation
step followed by phosphatase-conjugated streptavidin; and
ﬁnally an AP kit (Vector) to visualize the phosphatase
activity. All single-stained sections were counterstained
with Mayer’s hematoxylin (Fluka). The expression of sin-
gle and double stained cells was counted in each entire
section at 200· magniﬁcation using a standard binocular
light microscope (Olympus, Tokyo, Japan) equipped with a
0.5 · 0.5 mm ocular grid. The number of cells in the
epidermis was expressed per mm and the number in the
dermis per mm
2.
During a follow up period of 1 year, visits were
scheduled every 6 months. In case a patient experienced a
relapse in between follow up visits, or after the initial
1 year follow up period, extra visits were performed at the
patient’s initiative for additional monitoring and treatment.
Patients without a relapse on record were interviewed by
telephone to exclude disease reoccurrence. The Wilcoxon
rank sum test was used for statistical analysis of cell counts
between samples before and after remission and the
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ered signiﬁcant.
Results
Eighteen patients entered this study with a mean age of
43.9 ± 11.5 years at the time of inclusion (mean age of
12 males was 41.7 ± 10.9 and for 6 females
48.4 ± 12.3 years). The mean disease duration was
4.7 ± 3.3 months (Table 1). Lesional biopsies were taken
from the lower leg in 14 cases, 3 times from the trunk and
in 1 patient from the wrist. Fourteen patients were treated
with oral prednisone, two patients received local cortico-
steroid treatment, one psoralen and ultraviolet A photo
therapy and one acitretin. Three patients were lost to follow
up, two patients refused biopsies after remission but their
relapse data could be recorded. From the remaining 13
patients, biopsies could be collected after remission. The
mean treatment duration until remission was
136 ± 60 days (in the prednisone treated subgroup
134 ± 60 days, in the subgroup who received other treat-
ment modalities 148 ± 74 days). In 4 out of 13 biopsies a
minimal remnant inﬂammatory inﬁltrate around the basal
layer was still present, in spite of clinical remission.
During follow up (with a minimum period of
30 months) 9 out of 16 patients experienced a relapse of
lichen planus symptoms, 6 patients within 1 year, 3 within
4 years. All relapses occurred in patients treated with oral
prednisone. In 2 patients with relapses, remnant inﬂam-
mation after remission had been noticed.
In 11/18 (61%) patients lichen planus affected skin
contained HHV-7 speciﬁc DNA before treatment compared
to 1/13 (8%) patients after remission (P = 0.01, McNemar
test). In one patient (no. 15) HHV-7 DNA was detected
after remission whereas before treatment no HHV-7 DNA
was found.
Immunohistochemical single staining for the presence of
HHV-7 tegument protein revealed that before treatment the
mean number of HHV-7 positive cells was 58.9 ± 33.4 per
mm
2 in the dermis and 12.7 ± 11.7 per mm in the epi-
dermis (Fig. 1). After remission the number of positive
cells had dropped to 13.3 ± 12.2 and 3.3 ± 2.2, respec-
tively (P < 0.05 with the paired samples t test).
Immunohistochemical double staining was performed
on skin specimens of four patients to investigate whether
HHV-7 protein expression may be associated with T cells
or plasmacytoid dendritic cells, which both represent
major constituents of the inﬂammatory inﬁltrate. We
found a considerable number of HHV-7/BDCA-2 double
positive cells in lesional lichen planus skin before treat-
ment but not after treatment (Fig. 2). The number of
single stained BDCA2 positive cells decreased approxi-
mately twofold ‘‘before treatment’’ compared to ‘‘after
remission’’ (Table 1). With HHV-7/CD3 double staining,
we predominantly observed single stained HHV-7 or CD3
cells whereas only an occasional double positive cell
could be found (Fig. 3).
Discussion
Lichen planus is characterized by a band-like lymphocytic
inﬁltrate, which seems to be involved in an attack of the
basal epidermal layer. It is suggested that these T lym-
phocytes are directed towards infected skin cells express-
ing viral antigens. Molecular mimicry is a second
conceivable inﬂammatory mechanism initiated by micro-
bial antigens or microbial-reactive T lymphocytes that
cross react with self antigens sharing homology (i.e., basal
layer structures).
In our previous study we localized HHV-7 pp85 antigen
containing cells in lesional lichen planus tissue around de
dermo-epidermal junction, coinciding with the location of
the inﬂammatory inﬁltrate [5]. In addition, we detected
high numbers of plasmacytoid dendritic cells (cells that are
associated with the clearance of virally induced diseases)
within the inﬁltrate. The presence of HHV-7 DNA and
HHV-7 antigen did not coincide with non-lesional lichen
planus skin, psoriatic skin and normal skin from healthy
donors. Since HHV-7 was not found in psoriatic skin
(which is also characterized by a lymphocytic inﬁltrate) it
is unlikely that HHV-7 in lichen planus is a reﬂection of an
innocent bystander in a dense inﬂux of lymphocytes.
Moreover, in the current study we could localize HHV-7
protein, mainly in BDCA-2 positive plasmacytoid dendritic
cells and sporadic in CD3 positive lymphocytes. This is
remarkable since HHV-7 has been characterized as a
T-lymphotropic virus [10]. Our results suggest that plas-
macytoid dendritic cells can also host HHV-7. This is
conceivable since plasmacytoid dendritic cells express
CD4 [15], which is the main receptor used by HHV-7 to
enter target cells [21].
Here we investigated the effect of therapy-induced
remission of lichen planus on HHV-7 replication. Both the
number of HHV-7 DNA containing skin samples and the
absolute number of HHV-7 antigen containing skin cells
(in dermis and epidermis) diminished signiﬁcantly after
treatment-induced remission. Since we included a 2-week
washout period between treatment termination and
obtaining the post remission biopsies, a direct medication
effect on viral replication is unlikely. In contrast to a
fourfold diminution in HHV-7 positive cells after treat-
ment, there was only a twofold reduction in the number of
BDCA2 positive plasmacytoid dendritic cells. This makes
it unlikely that the diminished HHV-7 expression only
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123depends on a reduced number of plasmacytoid dendritic
cells after treatment. Whether plasmacytoid dendritic cells
are carriers of HHV-7 driving the disease activity or that
these cells are infected as innocent bystanders, or actively
induce the inﬂammatory process is not yet clear and needs
further study.
HHV-7, a member of the beta herpes virus subfamily
was ﬁrst discovered by Frenkel et al. [10] in CD4 positive
T lymphocytes of healthy individuals. It is an ubiquitous
virus with a worldwide prevalence exceeding 90%. Most of
the primo infections occur during infancy [1]. Since the
discovery of HHV-8 as the causative agent for Kaposi
sarcoma [3], all three human herpes viruses (HHV-6, -7
and -8) discovered in the last few decades have been
subjected to studies on their role in skin diseases of un-
known origin like pitryasis rosea [7] and exanthema subi-
tum [2, 19].
A shared characteristic of all herpes viruses is their
unique ability to persist in the host after primary infection,
and become reactivated later in life (sometimes after many
years of latency). Symptomatic reactivation of herpes
viruses is a well-known phenomenon in the daily derma-
tological practice. For example, shingles afﬂicting patients
later in life after acquisition of the causative varicella
zoster virus during childhood, and the recurrence of labial
and genital herpes simplex virus lesions after reactivation
of viral DNA. Human herpes virus 6 reactivation is be-
lieved to cause the drug related exanthema and systemic
side effect syndrome (DRESS) [6].
It is unlikely that HHV-7 primary infections cause li-
chen planus, since ﬁrst transmission mostly occurs during
childhood, whereas lichen planus affects mainly patients
during midlife. Yet, it is conceivable that HHV-7 reacti-
vation triggers lichen planus, in the same fashion as Ep-
stein-Barr virus reactivation is associated with Burkitt
lymphoma.
The apparent paradoxical efﬁcacy of steroid therapy in
lichen planus and a considered viral cause can be explained
by a ‘‘hit and run’’ model where the actual viral reacti-
vation would be short lived but subsequently responsible
for an independently propagated inﬂammatory skin reac-
tion. This could also explain why not in all patients HHV-7
was detected at the time of inclusion. Moreover, in one
patient (no. 15) HHV-7 DNA was detected after remission.
It is this patient that experienced a relapse 1 month later
and returned to the clinic for additional treatment. Possibly
HHV-7 can trigger lichen planus episodes, including re-
lapses, but resolve before clinical lichen planus symptoms
appear. The other patient (no. 4) with a relapse within
1 month unfortunately refused us a post remission skin
sample. On the other hand, the absence of HHV-7 repli-
cation in some of our patients could also be explained
assuming a multi causal pathogenesis for lichen planus.
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Fig. 1 Mean cell count (in mm for the epidermis and mm
2 for the
dermis) of HHV-7 tegument pp85 positive cells with immunohisto-
chemical staining in lichen planus affected epidermis and dermis,
before treatment (white bars) and after remission (black bars). * and #
P < 0.05 with the Wilcoxon rank sum test
Fig. 2 Double positive stained plasmacytoid dendritic cells reﬂects
intracellular HHV-7 protein. BDCA-2 positive plasmacytoid dendritic
cells (blue stain) containing HHV-7 protein (red stain) in lesional LP
skin before (a) and after (b) treatment (overview 200· and inlay 400·
magniﬁcation)
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123Further evidence for the causal association of HHV-7
and lichen planus could come from clinical studies on the
efﬁcacy of anti-herpetic medication. Which drug would be
the best option is not yet clear. Guanoside analogons with
little side effects like acyclovir show little activity against
HHV-7 [8]. HHV-7 is more susceptible to cidofovir and
foscarnet but these drugs are known for serious side effects
[20].
Fredericks and Relman proposed a reconsideration of
Koch’s postulates for the identiﬁcation of microbial anti-
gens as causative agents in diseases [9]. With data pre-
sented here and in our previous study [5] we were able to
meet with three out of their seven postulates for the
establishment of a causal relationship between HHV-7
and lichen planus. (1) Microbial nucleic acid sequences
were present in most cases in diseased sites and not in
sites that lack pathology. (2) Fewer nucleic acid se-
quences were found in hosts without the disease. (3)
Nucleic acid sequences correlates were present at a cel-
lular level. The fourth postulate, a decrease of the number
of nucleic acid sequences during resolution of the disease
and increase with relapse, was met in this study as far as
disease resolution is concerned. Unfortunately we did not
collect lesional biopsies in those patients that suffered
from relapses. HHV-7 reactivation during relapses will
have to be investigated in future studies. (5) The number
of nucleic acid sequences should correlate with disease
severity and (6) reproducibility of the evidence will have
to be met in future longitudinal studies. The seventh
postulate, clinical features and pathology should be con-
sistent with known biological characteristics of the mi-
crobe, will also have to be addressed in future studies
since still little is known about the effects of HHV-7
in vivo yet. The hypothesis of HHV-7 as the causative
agent for lichen planus deserves further research in larger
studies.
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